For the Inventor, By the Inventor

Enter assignee name

Crystal Pharmatech Co., Ltd.

USPTO Granted Patents = 22

CIPO Patents = 6

EPO Patents = 12

Trademarks = 1

Forward Citations = 36

Loading Chart...

Loading Chart...

17 inventors (with patents filed for the assignee):

Yanfeng Zhang (22 out of 59 patents)

Minhua Chen (22 out of 55 patents)

Xiaoyu Zhang (20 out of 44 patents)

4. Chaohui Yang (6 out of 16 patents)

5. Xiaojuan Diao (6 out of 6 patents)

6. Jiaoyang Li (4 out of 5 patents)

7. Pixu Li (3 out of 11 patents)

8. Kai Liu (3 out of 32 patents)

9. Nan Xia (3 out of 6 patents)

10. Peng Wang (3 out of 12 patents)

11. Liang Zhang (3 out of 127 patents)

12. Po Zou (2 out of 6 patents)

13. Qiyue Liu (1 out of 3 patents)

14. Jinqiu Wang (1 out of 5 patents)

15. Shu Yu (1 out of 5 patents)

22 patents: Sort by Forward Citations

1. 10577334 - Crystalline form E of tafamidis meglumine, process for preparation and use thereof (2020-03-03),

2. 10562855 - Crystalline form of lenvantinib mesylate and process of preparation thereof (2020-02-18),

3. 10544129 - Crystalline forms of AP26113, and preparation method thereof (2020-01-28),

4. 10508087 - Crystalline forms of trisodium supramolecular complex comprising valsartan and AHU-377 and methods thereof (2019-12-17),

5. 10487064 - Crystalline forms of selective S1P1 receptor modulator and preparation method thereof (2019-11-26),

6. 10472369 - Crystalline forms of (6-(1H-indazol-6-yl)-N-[4-(4-(4-morpholinyl)phenyl]imidazo[1,2-A]pyrazin-8-amine) methanesulfonate (2019-11-12),

7. 10442775 - Preparation method for eutectic hydrate crystal form II of AHU-377 and diovan trisodium salt (2019-10-15),

8. 10377757 - Crystal form of JAK inhibitor and preparation method thereof (2019-08-13),

9. 10351536 - Crystalline forms of lesinurad and its sodium salt (2019-07-16),

10. 10323035 - Co-crystal of a CDK inhibitor and an MEK inhibitor and process of preparation thereof (2019-06-18),

11. 10308641 - Crystal form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxole-5-yl)cyclopropane formamido)-3-methylpyridine-2-yl)benzoic acid and preparation method thereof (2019-06-04),

12. 10273262 - Crystalline form A of obeticholic acid and preparation method thereof (2019-04-30),

13. 10266523 - Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4'-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof (2019-04-23),

14. 10246437 - Crystal form of neratinib maleate and preparation method therefor (2019-04-02),

15. 10246418 - Crystal form of lenvatinib methanesulfonate salt and preparation method thereof (2019-04-02),

Crystal Pharmatech Co., Ltd. is a pharmaceutical research and development company. They specialize in providing solid-state and crystallization solutions, offering services such as polymorph screening, salt screening, cocrystal screening, and crystallization process development. Their team of experts combines advanced technologies with industry expertise to help clients optimize drug discovery and development processes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

22 Patents

#23 in Suzhou

#1,195 in China

#27,885 in the World

Crystal Pharmatech Co., Ltd.

Forward Citations = 36

17 inventors:

Yanfeng Zhang (22 out of 59 patents)

Minhua Chen (22 out of 55 patents)

Xiaoyu Zhang (20 out of 44 patents)

4. Chaohui Yang (6 out of 16 patents)

5. Xiaojuan Diao (6 out of 6 patents)

Please report any incorrect information to support@idiyas.com

Loading…